In this episode Oriel chats to Jennifer Chow, CEO & managing director of Chimeric Therapeutics (ASX:CHM) and Dr Deborah Rathjen, CEO of Carina Biotech.
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers.
The panel discuss a range of topics including where we are on the road to finding a cure to cancer, CAR-T treatments, R&D capital and who is paying for it, collaborations in the CAR-T field, what investors can expect from these companies in the next 12 months.
In this episode Oriel chats to Jennifer Chow, CEO & managing...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |